• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Von Rickenbach Josef H

    7/23/25 7:40:12 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    VON RICKENBACH JOSEF H

    (Last) (First) (Middle)
    C/O REIN THERAPEUTICS, INC
    12407 N. MOPAC EXPY. SUITE 250 #390

    (Street)
    AUSTIN TX 78758

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Rein Therapeutics, Inc. [ RNTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/23/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $1.55 07/23/2025 A 17,500 (1) 07/22/2035 Common Stock 17,500 $0.00 17,500 D
    Explanation of Responses:
    1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
    /s/ Brian Windsor, attorney-in-fact for Josef H. von Rickenbach 07/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RNTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNTX

    DatePrice TargetRatingAnalyst
    1/28/2025$8.00Buy
    Rodman & Renshaw
    More analyst ratings

    $RNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Aivado Manuel

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    7/23/25 7:42:24 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Von Rickenbach Josef H

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    7/23/25 7:40:12 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Musso Alan A

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    7/23/25 7:38:33 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    SEC Filings

    View All

    SEC Form 10-Q filed by Rein Therapeutics Inc.

    10-Q - Rein Therapeutics, Inc. (0001420565) (Filer)

    8/14/25 4:03:05 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

    7/30/25 9:04:36 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Rein Therapeutics Inc.

    424B5 - Rein Therapeutics, Inc. (0001420565) (Filer)

    7/30/25 8:59:41 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

    AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific Officer, Cory Hogaboam, and Chief Executive Officer, Brian Windsor, will each present at the IPF Summit 2025, taking place August 19-21, 2025, in Boston, MA. Dr. Hogaboam will present at 8:00 am on Tuesday in a workshop titled, "Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation." He will di

    8/14/25 5:00:00 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

    Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99 billion, represents one of the largest commitments to date for AI- and robotics-driven pharmaceutical R&D.

    8/6/25 7:56:00 PM ET
    $ENTA
    $RNTX
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has entered into two strategic financing agreements with an affiliate of Yorkville Advisors Global, LP, providing the potential for access to up to $21 million in capital. The financing includes: A $6 million pre-paid advance agreement, with an initial $1 million advance funded at signing.A $15 million standby equity purchase agreement (SEPA), which Rein may use at its discretion over 36 months, subject to

    7/30/25 8:30:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00

    1/28/25 7:16:42 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care